Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have not had time to keep up, but for me the question is can they make enough profit to pay off debt from the plant expansion, with out selling shares. A real profit this quarter is great news, but the increased sales may tie up working capital (receivables), unless the jobs are front end funded. Did we get a PE this quarter?
I still have some shares (long term hold), and if we get clarity on a good low running PE and the ability to earn their way out of debt, I will buy more shares, but for now I am not adding.
Took a minute and found this pertaining to possible competition for ESPH core market:
July 21, 2008 - Midland and Houston, TX
STW Resources Orders First GE Evaporator to Reclaim Waste Water in the U.S. Oil and Gas Industry
http://www.stwresources.com/_pdf/2008-07-21b.pdf
I have never been a big fan of evaporative systems, but that is a 4 year old PR. Not sure what STW is using now.
Oh, and FWIW, I watched a PBS special this week on the new water wars just starting in Texas now, between cities, farmers and oil and gas drillers......Due to the record drought!!!!
I won't have time (working 80 hrs.wk), but someone here should dig into this news, see if this is or will be competition to ESPH, or if it gives us market data for ESPH, or if it might even be an ESPH rig lurking in the news?
http://www.watertechonline.com/municipal-industrial/article/tests-reveal-stws-reclaimed-oil-produced-water-meets-standards-for-reuse
Perhaps from here?
http://www.fetcheveryone.com/viewtopic.php?id=49267&page=6
http://www.facebook.com/WoodardRacing
http://www.facebook.com/pages/Mastic-Blast-Drinks/312453322149840
But this is a major significant change:
www.lef.org/Vitamins-Supplements/Item01021/Intact-Digest.html
lef.org (Life extension) is a major internet retailer of vitamins and supplements (I buy from them), and I just discovered the IFUS "Intact Nutrition" is now on sale on their web site!!!!!!!
These guys have been around for a long time and have their own magazine!!!
http://www.lef.org/magazine/index.htm
Ah, Yes, I recall, just did not recall the Ihub alias. Been too long since we did chat about CABN.
You have far more patents, than I do :( LOL, but like you said, they are a double edge sword, and are a cash drain :(, and I agree, are frequently of limited value, and are useless if you can not convert them into profits and positive cash flow at some point, or PRs used to suck bag holders into buying worthless stock, LOL.
I also agree with "just make the damn thing work", but I will add "just get some real sales and profits" going as well. Only thing I ever really got out of my patents after 18 years was credentials that got me $$$ consulting work when all was said and done. My patents were 20 years too early for the market.
One of the things that had and has progressively annoyed and seriously concerned me about CABN, has been the long term lack of any real transparency. I once asked Byron by email if they would answer some questions I had, and I offered to sign a non-disclosure agreement to get those answers, but he would not even reply to my last 3 emails with a no, maybe, or ???s. And yes I used the right email. That was a RED FLAG to me!!!! The only emails Byron ever did reply to me with were back door stock offers made to accredited investors to buy new dilution shares at half of retail!!!! I still have those emails!!!
Oh, by the way, my last 2 patents involved novel catalysis, and CO2 reduction in a utility patent, so I am not a nob in the catalyst or CO2 conversion area. I was very disappointed to see them abandon the room temperature approach using organic enzymes to convert CO2 into methanol, and last time I checked there was still nothing publicly available in the US PTO office indicating any kind of patent application on file for that process or method. Then they went to dry reforming, which still included some CO2 conversion to organics, but now they just sound like a steam reforming catalyst for just CH4 conversion to larger organic molecules firm, in a ME-TOO process, which is not why invested here.
And there has been no further mention in a year now of the purported intention to up list shares to a major exchange like NASDAQ that they pumped in PRs when they did the $6/share reverse split from about .06/share (I forget the exact number), which I told everyone here a year ago would also never happen with this outfit, and I was hazed for that opinion too at the time. I also predicted a share price fall to $2 or less in 12 months, for CABN after the R/S, and was hazed for that opinion at the time on this board, yet here we are, nearly hitting $1 a share already, down about 75% with $2/share now strong resistance, and the stock pre split (before the 1:40 R/S) price is now trading at around .035/share, not far from an all time low set recently here during a huge bull market in other stocks.
I had hope here too, once, but hope is not eternal, LOL. One thing is for sure, if they ever really do get something going, there will be many more opportunities to buy cheaper shares, IMHO, before it really becomes a solid investment. Do you have PM here? If so drop me an email address....
There are an infinite number of ways to structure a deal, good and bad. But rest assured Wilmont will try and get all he can out of any deal for himself. The question is, will any buyers or JV partner's risk miss treating us. In some possible deals, they may want us!!!!!!
We are almost there :)
Thanks. All I can say at this point is they have been on the R&D cash burn trail for 4 years or more, with no sales. In the mean time my daughter started her own photography business at 21 and already has customers and sales, and is not burning though a $1,000,000/year of investor money.
I have seriously considered shorting a stock for the first time in my life, THIS one! But I will follow this one to glory or the grave, since I was the one pumping the hell out of it 2008-09 and buying shares, when THEY claimed to have new cutting edge technology, that turned out later to be vapor ware.
But you asked why I am here. I am here because I work in the environmental-chemical engineer sector, I am an inventor, with my own ISSUED patents in the sector, including one that addresses CO2 issues. My degree is in bio-chemical engineering. And I have tended to invest in what I know. But I will not put a dime in this one again unless they publish the patent applications, or get a utility patent issued that is not a junk patent, but one with real value, and get a real deal approved with a real firm like Shell to build a pilot plant, or actually sell something with IP that is verifiable to protect the product they sell. FWIW, I actually had issued patents, and working units and still failed to get my technology widely into the market and make money because of CO2 politics.
I have watched too many companies like this one get to the product stage and still fail miserably, Axion Power (another of my 2008 favorites like CABN) has the most incredible battery on the market (lead acid-Carbon-super capacitor-battery hybrid), DOD-DOE funding and backing, a working battery and some sales for 4 plus years, and they still are loosing 4-5 million per year. This one should have been selling a product 2 years ago. They have had 4 years to develop a product they could sell, and so far they have failed to even get a sell able product into field trials.
Hope that answers your why question?
LOL, I can't complain, I am getting to buy retirement shares for .0015 on the dollar.
He may be waiting for Israel to bomb Iran into the stone age, and oil to hit $200/share, and then sell into the panic. SE, I just took my Rolaids (LOL) so I may keep buying especially if the market cap hits $50,000, LOL! The lower it goes, the more pressure Wilmont will feel to get his act together. It was tempting at .003, at .0005 it will be irrestible, LOL
But, OTH this is the only -POS- I lost money on today (LOL, on paper that is), way to go Wilmont!!!
Interesting, and very positive! It was not clear what the end market is until their last statement:
We will continue our attention toward engaging with the EV industry
What is your opinion on this one. Is the dividend safe, or just a lure for the unwary while they dilute?
I book marked this one a while back, but have not really looked under the hood.
Sure. But I expect more of an investor effect. Investors have felt for some time that this sector was dead and finished. This is the kind of news that will attract old and new investors like to flies to honey!!!
The coal companies will take a hit here, and natural gas power plants have already taken the lead over coal even before the rule was proposed. But the Cement industry, Lafarge, can not solve their CO2 issue by switching from coal to cheaper, less CO2 emitting natural gas.
http://www.ipcc-nggip.iges.or.jp/public/gp/bgp/3_1_Cement_Production.pdf
Cement is an important construction ingredient produced in virtually all countries. Carbon dioxide (CO2) is a byproduct
of a chemical conversion process used in the production of clinker, a component of cement, in which
limestone (CaCO3) is converted to lime (CaO).
I think I recall seeing that and posting it here, on the search I did over the holidays. But I did not know the financial details. THANKS for the link!!!!!
I heard on TV news last night that EPA is issuing a new rule that will require 50% CO2 emissions reductions from any new Coal fired power plants in the USA!!!!
http://www.nytimes.com/2012/03/28/science/earth/epa-sets-greenhouse-emission-limits-on-new-power-plants.html?_r=1
http://epa.gov/carbonpollutionstandard/pdfs/20120327proposal.pdf
https://www.google.com/search?q=epa+co2+coal+power+plant+50%25+new+rule+news&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a
http://www.latimes.com/news/nationworld/nation/la-na-epa-emissions-20120328,0,4962478.story
http://www.bloomberg.com/news/2012-03-27/china-shows-u-s-how-to-push-for-carbon-capture.html
Last time I checked CABN dropped the plans to recycle CO2 completely, in favor of pursuing a wet steam catalyst market for converting CH4 to H2?
LOL, I thought that was MY opinion! LOL
I think it bottomed, unless the market tanks the next week or so before earnings season.
but what money do they have to acquire those assets
The wells do not need plugging if they are tested and pass the test. No doubt a few may fail the test and need plugging.
The TCEQ already said they could pump from the wells once tested and proven to pass the test, but that they could not sell the oil until the fines are paid.
24 million - 1.2 million (your number) is still a 22.8 million dollar bottom value for the field if sold.
22.8/148 = .154/share
I think you finally picked a winner, right time, right place, right stock. Now we just need to hope Wilmont finally does the smart thing, for once! Even a broken clock is right twice a day, LOL!
Rest assured, SE is not dumping his EGOH shares!!!! Nor am I.
The only real question is when will Wilmont finally sell, and or give up control, and under what terms. It is no secret that he is entertaining real offers. If you do not believe this, then make him and offer!
Well, no .08 shares for me it seems. Never got my buy filled :(
and we are up 85% today already, gone vertical, ballistic again!
Glad I kept the shares I had, LOL!
The 700,000 market cap is wrong, based on current data, more like $200,000.00 today.
Someone just bought 13,000 shares at .15!!!!! GO TGTX
With all the insiders at CYTR buying retail shares so heavily in Feb this year, shortly after the 8K was filled on the investment banker being hired, I think there must be a JV deal of some kind in the works that is going rocket this stock back to dollar land when most people least expect it. And last time I checked the institutions that were selling last year at .65-$1.00, have been buying at the .35 and lower area for almost 6 months now.
I am locked and loaded already. Looooong for the big move back up.
Today's news on great test results for Pancreatic cancer experiments may be the early news. Note that CYTR has world wide rights to the drug, the pancreatic test results showed complete remission of one the hardest to treat cancers there is, Pancreatic Cancer, according to today's news, so this may trigger multiple JV funding deals worldwide, and CYTR has the staff, and executives with the track record to make the deals!!!
CYTR), a biopharmaceutical company specializing in oncology, today announced the upcoming presentation of research demonstrating that INNO-206 in combination with either doxorubicin or a novel albumin-binding methotrexate drug induced complete tumor remissions in animal models of human pancreatic cancer. The results will be presented at the American Association for Cancer Research (AACR) 2012 Annual Meeting on Monday, April 2, 2012 in Chicago, Illinois. CytRx holds the worldwide rights to INNO-206, which is a tumor-targeted albumin-binding drug incorporating the widely used chemotherapeutic agent doxorubicin.
The posters will be presented by INNO-206 inventor Felix Kratz, Ph.D., Head of the Division of Macromolecular Prodrugs at the Tumor Biology Center, Freiburg. “These studies show that INNO-206 administered in combination with other chemotherapies has significant potential to more effectively treat pancreatic cancer. The combination of half maximum tolerated doses of INNO-206 and doxorubicin was much better tolerated than full doses of either INNO-206 or doxorubicin and was able to induce primarily complete and partial responses in the pancreatic tumor model,” Dr. Kratz said.
The two poster presentations are as follows:
* “Combination therapy of doxorubicin and the acid-sensitive albumin-binding prodrug of doxorubicin INNO-206 induces complete regressions in a xenograft pancreatic carcinoma model demonstrating excellent tolerability,” Kratz, et.al. This research evaluated the combination of doxorubicin and INNO-206 against each drug alone in varying dose levels and administered at different time intervals in a mouse model of human pancreatic cancer. Therapy with doxorubicin alone produced only moderate tumor inhibition, while the combination therapeutic arms as well as INNO-206 induced almost all complete and partial remissions, and the combination schedules were substantially less toxic.
“The surprising result from this study is that the combination of doxorubicin and INNO-206 has potent antitumor efficacy and is as active as INNO-206 alone, but systemic tolerability is distinctly superior without causing any body weight loss. This synergistic effect may be due to a combination of factors that result in a more homogenous distribution of the drugs within the tumor and tumor cells,” explained Dr. Kratz.
* “Combination therapy of an acid-sensitive albumin-binding prodrug of doxorubicin (INNO-206) and an albumin-binding prodrug of methotrexate (AW054) that is cleaved by cathepsin B and plasmin induces complete remissions against pancreatic cancer in vivo,” Kratz, et. al. This research showed that a combination of two albumin-binding drugs, INNO-206 and AW054, a derivative of methotrexate, administered at half their respective maximum tolerated dose levels in an animal model of pancreatic cancer produced complete remissions with acceptable body weight loss. By contrast, doxorubicin and methotrexate both administered at their maximum tolerated dose levels, or in combination showed only moderate antitumor effects when compared with control animals treated with saline.
“The encouraging result from this in vivo investigation is that all animals responded with a complete response in an essentially chemoresistant tumor indication when treated with two albumin-binding drugs,” Dr. Kratz summarized.
CytRx President and CEO Steven A. Kriegsman said, “These results could signal an important step forward in the treatment of patients with advanced pancreatic cancer, and they open exciting opportunities for CytRx to evaluate INNO-206 alone and in combination with other drugs, including doxorubicin. As the fourth most common cause of cancer death in the U.S. with only a 20% one-year survival rate, advanced pancreatic cancer represents a significant unmet medical need and patients would greatly benefit from a therapy that treats this tumor indication more effectively. CytRx intends to pursue Dr. Kratz’s exciting findings in human clinical trials.”
In a previously conducted preclinical animal study, Dr. Kratz showed that treatment with INNO-206 in an orthotopic human pancreatic cancer model resulted in a statistically significant three-fold reduction in the average primary tumor size, significantly outperforming gemcitabine and doxorubicin itself. Results from the trial were published in the peer-reviewed journal Investigational New Drugs and presented in a poster at the AACR Annual Meeting in April 2009.
CytRx has completed enrollment of a Phase 1b/2 clinical trial with INNO-206 in patients with advanced solid tumors (primarily soft tissue sarcomas), and has initiated an international Phase 2b clinical trial in patients with soft tissue sarcomas. The Phase 1b/2 clinical trial results will be presented by a premier soft tissue sarcoma expert at the American Society of Clinical Oncology (ASCO) meeting in early June. The Company also has announced plans in the second quarter of 2012 to begin a Phase 2 trial with INNO-206 in an undisclosed solid tumor indication.
Abstracts for the poster presentations are available at http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=43002f9a-df27-4e50-967a-7a0d201aa85e&cKey=8273344d-808e-4488-9e3f-aba9175f20c0&mKey={2D8C569E-B72C-4E7D-AB3B-070BEC7EB280} and http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=43002f9a-df27-4e50-967a-7a0d201aa85e&cKey=a6c8310c-641e-4997-9fd4-15dddae56489&mKey={2D8C569E-B72C-4E7D-AB3B-070BEC7EB280}.
About the AACR
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. For more information about the AACR, visit www.AACR.org.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. With its tumor-targeted doxorubicin conjugate INNO-206, CytRx has initiated an international Phase 2b clinical trial as a treatment for metastatic or unresectable soft tissue sarcomas, is completing its ongoing Phase 1b/2 clinical trial in patients whose tumors progressed on chemotherapy, primarily with soft tissue sarcomas, and plans to initiate a Phase 2 trial for an undisclosed solid tumor indication in the first half of 2012. CytRx's pipeline also includes tamibarotene, which it is testing in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and which is in a clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company evaluated bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about the Company, visit www.cytrx.com.
With the cat out of the bag now as to the SEC fraud(s) perpetuated by Pierce, Westbrook, MNLU, et. al., I seriously doubt MNLU will ever try and collect that debt, and seriously doubt AEXP will ever consider paying it. If MNLU ever raises cash, pays its debt and gets back on sound financial ground, I fully expect AEXP shareholders to sue MNLU, Westbrook, Pierce and the whole bunch. For now one can not get blood out of a turnip, and MNLU is a BK turnip IMHO.
Lol, an Optimist!!!!
And I think I know who it is!!!!! It values the company at $270,000 based on 147 million shares!!!! Which is dirt cheap.
LOL
They are, I picked it up reading a PR the last 2 years. Not sure how significant the dollars, and increased revenue are.
how do you know they are 1 of our customers ???
Unless MNLU strikes gold this week, and raises enough money to go on a pipeline building and well drilling spree, which has about 0.00000000% chance of happening with NG at about $2.34, I don't see the AEXP CEO taking any more chances on the back stabbers at MNLU and Westrock, or AEXP raising the cash to fund the AEXP share of any new well drilling costs on the MNLU controlled leases.
I think the only reason MNLU got in on the AEXP well in the first place, is MNLU had cash, AEXP needed cash, and AEXP thought they were in control by virtue of owning the lease where the first well was located.
I am still here in hopes that AEXP starts a new project free and clear of MNLU to drill for oil, in a new location. SE says the US is flush with oil and locations begging to be drilled for oil right now!!!
Interesting, looks like an MM slammed the price down at the close, with a deliberate walk down of the ask after huge volume at the ask in large block buys at .16/share. No daytrader or long would have done that, unless the daytrader wanted to short a penny, which does not happen. MM must be short!!!
I am factoring in Wilmont giving up control of the company, and a real oil company buying and taking control of the public company and the leases, instead of just buying the oil field leases, and leaving an EGOH shell behind with cash.
If that happens (a takeover) and they get busy and find most of the well casings intact, and start pumping $100 oil, then $1 per share stock is very possible. The last data we have on the OS is 147 million shares.
Last I heard from Larry they were piggy backing at a large trade show for free (or something like that, I was too busy that day to chat), LOL, and they were getting some free exposure, maybe something came of it, or they may be traveling to inspect equipment for Lafarge (pilot plant, parts vendor?), or tying up the 3.2 million $ deal overseas, who knows, I have no idea, but I am sure our faith in Larry is rock solid again, just look at the stock price, up over 1000% this year!!!!!!!
Our little engine that could stock is back today! Nice volume beating on the ask, and back at .16/share!!! NICE!!!
The butterflies in my stomach from holding longs the last few days are gone now, LOL!
It has been just under 150 million shares for over 6 months.
http://www.otcmarkets.com/stock/EGOH/company-info
Then .10/share is an easy target, and if he takes a deal where EGOH shareholders get future value, while Wilmont gives up total control to a real oil firm, then $1 share is also possible.
EPA in the USA is getting tough on Cement plant emissions at plants like Lafarge has!!! No wonder LaFarge decided to go with an MVTG pilot plant to reduce CO@ emissions. Read this, OUCH!!!!!
http://yosemite.epa.gov/opa/admpress.nsf/1e5ab1124055f3b28525781f0042ed40/48aa8dd28f3ab133852579750077751e!OpenDocument
I agree, it would depend on the price of the sale, the perceived value of the shares after the sale, which all depends on what deal Wilmont accepts. The only way to value right now is the industry standard value of the oil in the ground which wildcatdriller posted a while back of $2 max per barrel of oil reserves. That would price the stock at about .05 to .10/share based on the current known OS share count. But there are possible deals where it could go much higher, such as if Wilmont sells controlling interest in the company (Wilmont's shares) to a real oil company with a real track record, and they get the oil pumping this year. Then it could go to $1.00-.50/share, especially if the new owners buy back shares or already own a lot of the float. But a price over .10/share would take oil pumping and TRRC fines paid, and wells tested before it got that high.